Relation of cell viability and apoptosis with clinical remission following induction chemotherapy in ALL and AML

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 3, 2007, Pages 313-321

  Bhushan, B ^a   Ahuja, D ^a   Verma, S ^a   Saluja, S ^a   Siddiqui, S ^a   Kapur, Sujala ^a,b  

^a HAMDARD UNIVERSITY   (India)

^b SAFDARJUNG HOSPITAL   (India)

Author keywords

Acute leukemia; Apoptosis; Cell viability; Clinical remission; Flow cytometry

Indexed keywords

7 AMINODACTINOMYCIN; ASPARAGINASE; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL VIABILITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE;

APOPTOSIS; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; TUMOR CELLS, CULTURED;

EID: 35348875960     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fisher D.E.: Apoptosis in Cancer therapy: Crossing the threshold. Cell. 78:539-542, 1994.
2. Darzynkiewicz Z., Bruno S., Del Bino G., et al.: Features of apoptotic cells measured by flow cytometry. Cytometry. 13:795-808, 1992.
3. Ormerod M.G.: The study of apoptotic cells by flow cytometry. Leukemia. 12:1013-1025, 1998.
4. Hannun Y.A.: Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1845-1853, 1997.
5. Kerr J.F., Wyllie A.H., Currie A.R.: Apoptosis: a basis biolog-ical phenomenon with wide-ranging implication in tissue kinetics. Br. J. Cancer. 26:239-257, 1972.
6. Wyllie A.H., Kerr J.F., Currie A.R.: Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:251-306, 1980.
7. Allen R.T., Hunter W.J. 3rd, Agrawal D.K.: Morphological and biochemical characterization and analysis of apoptosis. J. Pharmacol. Toxicol. Methods. 37:215-228, 1997.
8. Schmid I., Uittenbogaart C.H., Keld B., Giorgi J.V.: A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J. Immunol. Methods. 170:145-157, 1994.
9. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperer C.: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J. Immun. Meth. 184:39-51, 1995.
10. Smith B.D., Bambach B.J., Vala M.S., et al.: Inhibited apoptosis and drug resistance in acute myeloid leukaemia. Br. J. Haematol. 102:1042-1049, 1998.
11. Norgaard J.M., Jensen P.D., Bendix K., Clausen N., Palshof T.: Relevance of in vitro leukaemia cell survival to short and long-term clinical outcome in AML. Leuk. Lymphoma. 32:327-337, 1999.
12. Savitskiy V.P., Shman T.V., Potapnev M.P.: Comparative measurement of spontaneopus apoptosis in pediatric acute leukemia by different techniques. Cytometry B Clin. Cytom. 56:16-22, 2003.
13. Ong Y.L., McMullin M.F., Bailie K.E., Lappin T.R., Jones F.G., Irvine A.E.: High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br. J. Haematol. 111:182-189, 2000.
14. Srinivas G., Kusumakumary P., Nair M.K., Panicker K.R., Pillai M.R.: Mutant p53 protein, Bcl-2/Bax ratios and apoptosis in paediatric acute lymphoblastic leukaemia. J. Cancer. Res. Clin. Oncol. 126:62-67, 2000.
15. Pallis M., Turzanski J., Grundy M., Seedhouse C., Russell N.: Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications. Br. J. Haematol. 120:1009-1016, 2003.
16. Lowenberg B., van Putten W.L., Touw I.P., Delwel R., Santini V.: Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N. Engl. J. Med. 328: 614-619, 1993.
17. Li X., Gong J., Feldman E., Seiter K., Traganos F., Darzynkiewicz Z.: Apoptotic cell death during treatment of leukemias. Leuk. Lymphoma. 13: 65-70, 1994.
18. Norgaard J.M., Langkjer S.T., Palshof T., Clausen N., Pedersen B., Hokland P.: Relation of blast cell survival and proliferation to chemotherapy resistance in AML. Br. J. Haematol. 93: 888-897, 1996.
19. Van Stijn A., van der Pol M.A., Kok A., et al.: Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica. 88:497-508, 2003.
20. Laupeze B., Amiot L., Drenou B., et al.: High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br. J. Haematol. 116: 834-838, 2002.
21. Peller S., Rotter V.: TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum. Mutat. 21:277-284, 2003.
22. Faderl S., Estrov Z.: The clinical significance of caspase regulation in acute leukemia. Leuk. Lymphoma. 40:471-481, 2001.
23. Carter B.Z., Kornblau S.M., Tsao T., et al.: Caspase-independent cell death in AML: Caspase inhibition in vitro with pancaspase inhibitors or in vivo by XIAP or Survivin does not affeet cell survival or prognosis. Blood. 102:4179-4186, 2003.
24. Wuchter C., Karawajew L., Ruppert V., et al.: Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 110: 154-160, 2000.
25. Styczynski J., Pieters R., Huismans D.R., Schuurhuis G.J., Wysocki M., Veerman A.J.: In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br. J. Haematol. 110: 813-818, 2000.
26. Holleman A., den Boer M.L., de Menezes R.X., et al.: The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood. 107:769-776, 2006.